|
|
Blood, 15 July 2006, Vol. 108, No. 2, pp. 630-637.
Prepublished online as a Blood First Edition Paper on March 23, 2006; DOI 10.1182/blood-2005-09-3898.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells
Bing Z. Carter,
Duncan H. Mak,
Wendy D. Schober,
Teresa McQueen,
David Harris,
Zeev Estrov,
Randall L. Evans, and
Michael Andreeff
From the Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, and the Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston.
Triptolide, a diterpenoid isolated from the Chinese herb Tripterygium wilfordii Hook.f, has shown antitumor activities in a broad range of solid tumors. Here, we examined its effects on leukemic cells and found that, at 100 nM or less, it potently induced apoptosis in various leukemic cell lines and primary acute myeloid leukemia (AML) blasts. We then attempted to identify its mechanisms of action. Triptolide induced caspase-dependent cell death accompanied by a significant decrease in XIAP levels. Forced XIAP overexpression attenuated triptolide-induced cell death. Triptolide also decreased Mcl-1 but not Bcl-2 and Bcl-XL levels. Bcl-2 overexpression suppressed triptolide-induced apoptosis. Further, triptolide induced loss of the mitochondrial membrane potential and cytochrome C release. Caspase-9 knock-out cells were resistant, while caspase-8–deficient cells were sensitive to triptolide, suggesting criticality of the mitochondrial but not the death receptor pathway for triptolide-induced apoptosis. Triptolide also enhanced cell death induced by other anticancer agents. Collectively, our results demonstrate that triptolide decreases XIAP and potently induces caspase-dependent apoptosis in leukemic cells mediated through the mitochondrial pathway at low nanomolar concentrations. The potent antileukemic activity of triptolide in vitro warrants further investigation of this compound for the treatment of leukemias and other malignancies.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. J. Leuenroth and C. M. Crews
Triptolide-Induced Transcriptional Arrest Is Associated with Changes in Nuclear Substructure
Cancer Res.,
July 1, 2008;
68(13):
5257 - 5266.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Z. Carter, D. H. Mak, W. D. Schober, M. F. Dietrich, C. Pinilla, L. T. Vassilev, J. C. Reed, and M. Andreeff
Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5
Blood,
April 1, 2008;
111(7):
3742 - 3750.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Phillips, V. Dudeja, J. A. McCarroll, D. Borja-Cacho, R. K. Dawra, W. E. Grizzle, S. M. Vickers, and A. K. Saluja
Triptolide Induces Pancreatic Cancer Cell Death via Inhibition of Heat Shock Protein 70
Cancer Res.,
October 1, 2007;
67(19):
9407 - 9416.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Wang, S. Yang, Y. Su, Z. Xiao, C. Wang, X. Li, L. Lin, B. M. Fenton, S. F. Paoni, I. Ding, et al.
Enhanced Antitumor Effect of Combined Triptolide and Ionizing Radiation
Clin. Cancer Res.,
August 15, 2007;
13(16):
4891 - 4899.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Leuenroth, D. Okuhara, J. D. Shotwell, G. S. Markowitz, Z. Yu, S. Somlo, and C. M. Crews
Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease
PNAS,
March 13, 2007;
104(11):
4389 - 4394.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
